Analyst Reco. Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Delayed Nasdaq Other stock markets 20:56:43 02/05/2024 BST			5-day change	1st Jan Change
0.6501 ^USD	-5.03%		-7.10%	+26.77%

04-01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT
03-29	Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	04-01	MT
Goldman Sachs Cuts Price Target on Atara Biotherapeutics to $0.50 From $3, Maintains Sell Rating	11-10	MT
Evercore ISI Downgrades Atara Biotherapeutics to In Line From Outperform	11-09	MT
HC Wainwright Downgrades Atara Biotherapeutics to Neutral From Buy	11-09	MT
Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31	11-09	MT
Citigroup Adjusts Atara Biotherapeutics Price Target to $1.40 From $2, Maintains Sell Rating	21/08/23	MT
HC Wainwright Adjusts Atara Biotherapeutics Price Target to $28 From $27, Maintains Buy Rating	14/06/23	MT
Canaccord Genuity Adjusts Price Target on Atara Biotherapeutics to $20 From $50, Maintains Buy Rating	09/05/23	MT
HC Wainwright Adjusts Price Target on Atara Biotherapeutics to $27 From $29, Maintains Buy Rating	09/02/23	MT
Mizuho Securities Reiterates Atara Biotherapeutics at Buy With $31 Price Target	07/02/23	MT
EF Hutton Initiates Atara Biotherapeutics at Buy With $25 Price Target	05/01/23	MT
Mizuho Securities Cuts Price Target on Atara Biotherapeutics to $31 From $39, Keeps Buy Rating	16/08/22	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $3 From $4, Keeps Sell Rating	09/08/22	MT
Citigroup Downgrades Atara Biotherapeutics to Sell From Neutral; Price Target is $3	20/07/22	MT
Stifel Cuts Atara Biotherapeutics to Hold From Buy, Price Target to $5 From $16	13/07/22	MT
JPMorgan Downgrades Atara Biotherapeutics to Neutral From Overweight; Price Target is $10	13/07/22	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $4 from $5, Keeps Sell Rating	24/05/22	MT
HC Wainwright Adjusts Atara Biotherapeutics' Price Target to $29 from $31, Keeps Buy Rating	23/05/22	MT
Citigroup Downgrades Atara Biotherapeutics to Neutral From Buy, Sets $8 Price Target	09/05/22	MT
Stifel Adjusts Price Target for Atara Biotherapeutics to $18 From $20, Maintains Buy Rating	06/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Analyst Reco.

Filters